<DOC>
	<DOCNO>NCT00419081</DOCNO>
	<brief_summary>The purpose study determine whether Forodesine Hydrochloride effective treating patient relapsed/refractory precursor T-Lymphoblastic Leukemia/Lymphoma fail two prior treatment regimen .</brief_summary>
	<brief_title>Study Forodesine Hydrochloride Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two More Prior Treatment Regimens</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Patients unequivocal histologic diagnosis precursor Tlymphoblastic leukemia/lymphoma ( World Health Organization [ WHO ] classification ) . Failure respond relapsed two treatment regimen disease , one could HSCT . Performance status 2 Eastern Cooperative Oncology Group ( ECOG ) criterion ( see Appendix A ) . Eighteen year age older . Life expectancy least three month . Adequate liver function ( aspartate aminotransferase [ AST ] and/or alanine aminotransferase [ ALT ] â‰¤3 time upper limit normal ) , unless relate underlying leukemia . Negative serum urine pregnancy test within two seven day prior start study treatment female childbearing potential . Females childbearing potential male must willing able use adequate method contraception avoid pregnancy duration study manner risk pregnancy minimize . Acceptable contraceptive include intrauterine device ( IUDs ) , hormonal contraceptive ( oral , depot , patch , injectable ) , doublebarrier method condom diaphragms spermicidal gel foam . Signed informed consent form ( ICF ) prior start studyspecific procedure . Willing able provide authorization use disclosure personal health information accordance Health Insurance Portability Accountability Act ( HIPAA ) policy ( U.S. patient ) . Patients know human immunodeficiency virus ( HIV ) infection human T lymphotrophic virus 1 ( HTLV1 ) . Patients active hepatitis B C infection . Patients clinical evidence active central nervous system ( CNS ) leukemia . Active serious infection control oral intravenous antibiotic . Patients calculate creatinine clearance &lt; 50 mL/min . Prior treatment investigational antileukemic chemotherapy agent within seven day prior study entry lack full recovery side effect due prior therapy , independent therapy give . Rapidly progressive disease compromise organ function judge life threaten Investigator . Concurrent treatment antileukemia agent ( CNS prophylaxis [ e.g. , intrathecal methotrexate , cytarabine , hydrocortisone ] corticosteroid use exclude , must first approve Medical Monitor ) ( see Sections 9.2.1 9.2.2 ) . Pregnant and/or lactate female . Patients swallow chronic gastrointestinal disease condition may hamper compliance and/or absorption product . Hypersensitive intolerant component study drug formulation . Patients receive prior forodesine treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>leukemia</keyword>
	<keyword>lymphoma</keyword>
</DOC>